T0	Participants 75 132	early-stage non-small-cell lung cancer (IFCT 0002 trial).
T1	Participants 282 338	resectable StageI-II non-small-cell lung cancer (NSCLC).
T2	Participants 837 868	RESULTS A total of 528 patients
T3	Participants 2034 2054	in early-stage NSCLC